within Pharmacolibrary.Drugs.ATC.C;

model C02AC01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0021000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 0,            
    Vdp             = 0.0070999999999999995,
    k12             = 1.9,
    k21             = 1.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02AC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Clonidine is a centrally acting alpha-2 adrenergic agonist commonly used for the treatment of hypertension and attention-deficit hyperactivity disorder (ADHD), and as adjunct therapy in opioid withdrawal and analgesia. It is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>PK parameters reported for healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li><p>Blackburn, L, et al., &amp; Anderson, BJ (2014). Intranasal clonidine pharmacokinetics. <i>Paediatric anaesthesia</i> 24(3) 340–342. DOI:<a href=&quot;https://doi.org/10.1111/pan.12297&quot;>10.1111/pan.12297</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24467572/&quot;>https://pubmed.ncbi.nlm.nih.gov/24467572</a></p></li><li><p>Lowenthal, DT, et al., &amp; MacGregor, TR (1988). Clinical pharmacokinetics of clonidine. <i>Clinical pharmacokinetics</i> 14(5) 287–310. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198814050-00002&quot;>10.2165/00003088-198814050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3293868/&quot;>https://pubmed.ncbi.nlm.nih.gov/3293868</a></p></li><li><p>MacCarthy, EP, &amp; Bloomfield, SS (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i> 3(4) 193–219. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1983.tb03252.x&quot;>10.1002/j.1875-9114.1983.tb03252.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6310529/&quot;>https://pubmed.ncbi.nlm.nih.gov/6310529</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02AC01;
